Made available in DSpace on 2015-03-03T14:03:53Z (GMT). No. of bitstreams: 1
MariaMCA_DISSERT.pdf: 1294142 bytes, checksum: 64dee49ca0e00aab7f3d623528da9204 (MD5)
Previous issue date: 2006-05-17 / Considering that osteopenia and osteoporosis are diabetes mellitus
complications, and that tamoxifen (TAM) is an anti-estrogenic drug used in
breast cancer treatment, this drug may have a beneficial action preventing
accentuaded bone loss associated to diabetes. Female Wistar rats (n=60)
weighting 180-250g were divided in four groups: Group C, control animals
(n=5); Group T, animals treated with TAM (n=5); Group D, diabetic animals
(n=5); and Group DT, diabetic animals treated with TAM (n=5). Oestrus cycle
was evaluated before the beggining of experimental period to select the animals
with regular cycle. This evaluation continued throughout the study period and
for all studied groups. Diabetes was induced by a intra perithoneal injection of
streptozotocin (STZ) in a concentration of 45 mg/Kg of body weight. Those
animals with serum glicose levels 250 mg/dL were considered diabetics.
Animals were sacrificed in the periods of 30, 60 and 90 days after diabetes
onset. Left femur histomorphometric measurements and serum biochemical
analysis (glycemia, alkaline phosphatase, tartaric-resistant acid phosphatase,
calcium, phosphorous, magnesium, total proteins, albumin, globulins, urea and
creatinine) were done. Histomorphometric results showed a progressive bone
loss in Group D animals when compared to those from Group C all over the
experimental period, becoming accentuaded in the 90 days period. In relation to
Groups T and DT, values approcimated to those obtained for control group
were found during the whole period of study. Those data may indicate a bone
mass recovery or a diminished bone loss due to diabetes when animals were
treated with TAM. During the whole experimental period animals of groups D
and DT maintained glycemic levels above 250 mg/dL whereas animals of
groups C and T maintained those levels below 150mg/dL. Alkaline phosphatase
activity was increased in all study periods for groups D and DT when compared
to group C animals over the 90 days period. Tartarate-resistant acid
phosphatase activity was showed unaltered in all periods of study and for all
groups. Calcium and magnesium results were also unaltered, maintaining
reference levels for all groups in all experimental periods. Phosphorous levels
were increased in groups D and DT when compared to groups C and T in the
30 days period. However no difference was found in the periods of 60 and 90
days for this test. No difference was found for total proteins levels for groups C,
T, D and DT over the study period. Albumin levels were reduced in DT group in
the 60 days period and in D and DT groups in the 90 days period. Urea levels
were significantly increased in the 30, 60 and 90 days study periods in groups D
and DT when compared to groups C and T. Creatinine results showed a
significantly increase in the 90 days period for groups D and DT when
compared to groups C and T, and maintaining unaltered in the 30 and 60 days
periods. These results suggest that the treatment with TAM may reduce bone
loss caused by diabetes mellitus / A influ?ncia do tratamento com Tamoxifeno (TAM) na densidade mineral
?ssea foi estudada em ratos Wistar f?meas diab?ticos. Foram utilizados 60
ratos Wistar f?meas (180-250g), sendo divididos em quatro grupos: controle
C (n=5), tratado com TAM T (n=5), diabete D (n=5) e diabete tratado com
TAM DT (n=5). Foi feita avalia??o do ciclo estral durante 15 dias antes do
in?cio do experimento para selecionar os animais com ciclos regulares e
durante os per?odos de 30, 60 e 90 dias, em todos os grupos estudados. O
diabete foi induzido com inje??o intraperitoneal de estreptozotocina STZ
(45 mg/Kg) e os animais foram sacrificados em per?odos de 30, 60 e 90 dias
ap?s a instala??o do diabete melito (glicemia ?? 250 mg/dL). Foram
realizadas medidas histomorfom?tricas dos f?mures esquerdos e an?lises
bioqu?micas de glicose, fosfatase alcalina, fosfatase ?cida tartarato
resistente, c?lcio, f?sforo, magn?sio, prote?nas totais, albumina, globulina,
ur?ia e creatinina em amostras de soro. Os resultados histomorfom?tricos
mostraram uma perda progressiva de massa ?ssea, nos f?mures dos
animais do grupo D comparados ao grupo C em todos os per?odos
estudados. O grupo T se manteve sem altera??o nos per?odos e em rela??o
ao grupo DT observou-se que os valores da an?lise histomorfom?trica
mantiveram-se pr?ximos ao grupo C em todos os per?odos estudados,
indicando um aumento de massa ?ssea induzido pelo uso de TAM. Durante
todo o experimento a glicemia dos animais D e DT manteve-se sempre
acima de 250mg/dL e do grupo C e T inferior a 150mg/dL. A atividade da
fosfatase alcalina esteve aumentada em todos os per?odos estudados para
os grupos D e DT quando comparados ao grupo C. O f?sforo nos grupos D e DT encontrou-se aumentado quando comparado ao grupo C e T no
per?odo 30 dias. J? nos per?odos 60 e 90 dias n?o foram observadas
altera??es significativas nos grupos estudados. A albumina encontrou-se
diminu?da no grupo DT per?odo 60 dias e nos grupos D e DT no per?odo 90
dias. Em rela??o a ur?ia encontramos aumento significativo nos per?odos
30, 60 e 90 dias para os grupos D e DT em rela??o aos grupos C e T. A
creatinina teve aumento significativo no per?odo 90 dias para os grupos D e
DT quando comparados ao C e T, mantendo-se inalterada em todos os
grupos nos per?odos 30 e 60 dias. Para a fosfatase ?cida tartaratoresistente,
c?lcio, magn?sio e prote?nas totais n?o houve altera??o nos
per?odos estudados para todos os grupos. Os resultados obtidos confirmam
a a??o ben?fica de TAM no osso indicando um aumento de massa ?ssea
em ratos wistar diab?ticos tratados com TAM
| Identifer | oai:union.ndltd.org:IBICT/oai:repositorio.ufrn.br:123456789/18544 |
| Date | 17 May 2006 |
| Creators | Almeida, Maria Margareth C?mara de |
| Contributors | CPF:05410395808, http://lattes.cnpq.br/4245215108740331, Catanho, Maria Teresa Jansem de Almeida, CPF:14967898491, http://lattes.cnpq.br/2204048396738679, Ramos, Ana Maria de Oliveira, CPF:04045599487, http://lattes.cnpq.br/2365612055067945, Almeida, Maria das Gra?as, Rezende, Adriana Augusto de |
| Publisher | Universidade Federal do Rio Grande do Norte, Programa de P?s-Gradua??o em Ci?ncias Farmac?uticas, UFRN, BR, Bioan?lises e Medicamentos |
| Source Sets | IBICT Brazilian ETDs |
| Language | Portuguese |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/masterThesis |
| Format | application/pdf |
| Source | reponame:Repositório Institucional da UFRN, instname:Universidade Federal do Rio Grande do Norte, instacron:UFRN |
| Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0022 seconds